Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese Vs. Non- Obese Women

Overview

Journal Med Arch

Specialty General Medicine

Date 2020 Oct 12

PMID 33041447

Citations 42

Authors

Zaheera Saadia

Affiliations

Soon will be listed here.

Abstract

Introduction: Polycystic Ovary Syndrome (PCOS), the most common endocrinological problem among women in the reproductive age, is characterized by chronic ovulatory dysfunction, hyperandrogenism, and raised Luteinizing hormone : Follicle Stimulating Hormone (LH:FSH) ratio. Obesity and insulin resistance have been linked to PCOS. However, there is recently a growing population of thin, lean women who are diagnosed with PCOS.

Aim: This study aimed to compare normal and high Body mass index (BMI) women with PCOS and to investigate the correlation between BMI and LH/FSH ratio.

Methods: It was a case -control study at the Department of Obstetrics and Gynaecology, Qassim University clinic, Saudi Arabia. Women with PCOS were included in the study and were classified according to their BMI. Their computerized records were retrieved for the demographic, clinical, and laboratory data. The study groups were compared by the t-test and the Spearman correlation between BMI and LH/FSH ratio was calculated.

Results: A total of 63 women were included in this study (normal BMI group: n=30, and high BMI group: n=33). There was no difference between the two groups in terms of the LH/FSH ratio (2.76 vs. 2.79, P=0.48). There was no significant correlation between BMI and LH/FSH ratio, prolactin, or Thyroid stimulating hormone (TSH ) levels (Spearman correlation with >0.05).

Conclusion: The data suggests that the body mass index was not correlated with increased LH/FSH ratio. Since LH/FSH ratio was the same in normal BMI women, healthcare professionals need to think about ways to normalize this ratio beyond weight reduction.

Citing Articles

Diagnosis and Treatment of Adolescent Polycystic Ovary syndrome:A Review.

Zhang Y, Yang K, Fan T, Zheng D, Liu H Int J Womens Health. 2025; 17:459-474.

PMID: 39995885 PMC: 11847718. DOI: 10.2147/IJWH.S506498.

The Impact of BMI on PCOS Patients and Transcriptome Profiling and Bioinformatic Analysis of Granulosa Cells in PCOS Patients with High and Low BMI.

Tao P, Yan X, Li Y, Wang Z Reprod Sci. 2025; .

PMID: 39821799 DOI: 10.1007/s43032-024-01783-6.

Acupuncture for hormonal readiness and gut microbiota in obese polycystic ovary syndrome: an open-label, randomized controlled trial.

Wu T, Xu G, Hong X, Fan H, Zeng J, Liu Y Front Endocrinol (Lausanne). 2025; 15:1509152.

PMID: 39749020 PMC: 11693447. DOI: 10.3389/fendo.2024.1509152.

Effect of basal luteinizing hormone/follicle-stimulating hormone ratio on clinical outcome of fertilization in patients with polycystic ovarian syndrome: a retrospective cohort study.

Shan D, Zhao J, Lu X, Zhang H, Lu J, Shen Q PeerJ. 2024; 12:e18635.

PMID: 39619191 PMC: 11606322. DOI: 10.7717/peerj.18635.

Hyperandrogenism and anthropometric parameters in women with polycystic ovary syndrome.

Mansour A, Noori M, Hakemi M, Haghgooyan Z, Mohajeri-Tehrani M, Mirahmad M BMC Endocr Disord. 2024; 24(1):201.

PMID: 39333998 PMC: 11438141. DOI: 10.1186/s12902-024-01733-y.

References

Banaszewska B, Pawelczyk L, Spaczynski R, Dziura J, Duleba A . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab. 2006; 92(2):456-61. DOI: 10.1210/jc.2006-1988. View

Diamanti-Kandarakis E, Christakou C, Marinakis E . Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des. 2012; 18(3):270-82. DOI: 10.2174/138161212799040457. View

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003; 19(1):41-7. DOI: 10.1093/humrep/deh098. View

Wild R, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale H, Futterweit W . Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95(5):2038-49. DOI: 10.1210/jc.2009-2724. View

McKenna T . Pathogenesis and treatment of polycystic ovary syndrome. N Engl J Med. 1988; 318(9):558-62. DOI: 10.1056/NEJM198803033180906. View

Banaszewska B, Pawelczyk L, Spaczynski R, Duleba A . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab. 2011; 96(11):3493-501. PMC: 3205889. DOI: 10.1210/jc.2011-0501. View

Cai J, Zhang Y, Wang Y, Li S, Wang L, Zheng J . High Thyroid Stimulating Hormone Level Is Associated With Hyperandrogenism in Euthyroid Polycystic Ovary Syndrome (PCOS) Women, Independent of Age, BMI, and Thyroid Autoimmunity: A Cross-Sectional Analysis. Front Endocrinol (Lausanne). 2019; 10:222. PMC: 6467931. DOI: 10.3389/fendo.2019.00222. View

Goodarzi M, Dumesic D, Chazenbalk G, Azziz R . Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4):219-31. DOI: 10.1038/nrendo.2010.217. View

Legro R, Arslanian S, Ehrmann D, Hoeger K, Murad M, Pasquali R . Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12):4565-92. PMC: 5399492. DOI: 10.1210/jc.2013-2350. View

10.

Yen S . The polycystic ovary syndrome. Clin Endocrinol (Oxf). 1980; 12(2):177-207. DOI: 10.1111/j.1365-2265.1980.tb02132.x. View

11.

Johansson J, Stener-Victorin E . Polycystic ovary syndrome: effect and mechanisms of acupuncture for ovulation induction. Evid Based Complement Alternat Med. 2013; 2013:762615. PMC: 3773899. DOI: 10.1155/2013/762615. View

12.

. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2011; 27(1):14-24. DOI: 10.1093/humrep/der396. View

13.

Yu Q, Wang J . Subclinical Hypothyroidism in PCOS: Impact on Presentation, Insulin Resistance, and Cardiovascular Risk. Biomed Res Int. 2016; 2016:2067087. PMC: 4960326. DOI: 10.1155/2016/2067087. View

14.

Beydoun H, Beydoun M, Wiggins N, Stadtmauer L . Relationship of obesity-related disturbances with LH/FSH ratio among post-menopausal women in the United States. Maturitas. 2011; 71(1):55-61. PMC: 3398813. DOI: 10.1016/j.maturitas.2011.10.010. View

15.

Yuan C, Liu X, Mao Y, Diao F, Cui Y, Liu J . Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study. J Biomed Res. 2016; 30(3):197-202. PMC: 4885167. DOI: 10.7555/JBR.30.20140111. View

16.

Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Franks S, Gambineri A . The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014; 171(4):P1-29. DOI: 10.1530/EJE-14-0253. View

17.

Balen A, Laven J, Tan S, Dewailly D . Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2004; 9(6):505-14. DOI: 10.1093/humupd/dmg044. View

18.

Goyal M, Dawood A . Debates Regarding Lean Patients with Polycystic Ovary Syndrome: A Narrative Review. J Hum Reprod Sci. 2017; 10(3):154-161. PMC: 5672719. DOI: 10.4103/jhrs.JHRS_77_17. View

19.

Esmaeilzadeh S, Andarieh M, Ghadimi R, Delavar M . Body mass index and gonadotropin hormones (LH & FSH) associate with clinical symptoms among women with polycystic ovary syndrome. Glob J Health Sci. 2015; 7(2):101-6. PMC: 4796454. DOI: 10.5539/gjhs.v7n2p101. View

20.

Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y . Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril. 2010; 94(6):2208-13. DOI: 10.1016/j.fertnstert.2009.11.045. View